Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Neuropathic pain: A Physiological perspective Introduction The word pain is thought to be derived from the Latin word poena, meaning punishment (Gu et al., 2005). “Pain is an unpleasant sensory and emotional experience, associated with actual or potential tissue damage, or described in terms of such damage” (Merskey, 1979, IASP). Pain is among the most common and distressing symptoms encountered by individuals, being one of the most common conditions limiting efficiency and diminishing quality of life (Mert et al., 2013). Pain serves an important vital function, i.e as a warning signal of tissue damage, resulting from an accidental trauma, infection, or inflammation. The process through which potentially damaging stimuli is detected is nociception. Thermal, chemical, or mechanical stimuli are strong enough to be capable of causing tissue damage (i.e.; noxious or nociceptive stimuli), activate specialized sensory neurons, commonly referred to as nociceptors, and to transmit the noxious signal to the central nervous system (CNS). Pain can be classified according to several variables, that includes; its duration (acute, convalescent, chronic), its pathophysiologic mechanisms (physiologic, nociceptive, neuropathic), and its clinical context (eg, postsurgical, malignancy related, neuropathic, degenerative) (Vadivelu et al., 2009). Pain is an early warning system that serves a protective function, which helps to limit exposure to damaging noxious stimuli, thus detection of noxious stimuli to prevent further contact is described as nociceptive pain (Woolf, 2010). A second kind of pain is described as being adaptive and protective by increasing pain sensitivity (low threshold to pain) to avoid tissue damage, thus allowing for proper healing by limiting physical movement. This kind of pain is called inflammatory pain because it involves the activation of the immune system by tissue injury (Woolf, 2010). The inflammation results in the generation of a plethora of chemical agents that are intended to fight infection and assist in the repair of injured tissue (White et al., 2010). Unfortunately, the body’s inflammatory response to injury, or disease, is often disproportionate, resulting in pain that is sometimes of such severity that it may hamper recovery or, in the longer term, result in disability (White et al., 2010). The third type of pain is not adaptive, lacks any protective role and serves no useful purpose; it is referred to as pathological pain (Meintjes, 2012). It may result from abnormal functioning of the nervous system (Neuropathic pain) or pain elicited in the absence of any noxious stimuli (Dysfunctional pain). It is characterized by intensified pain sensitivity, low threshold of pain in the absence of any noxious stimuli. Pathological pain has clinical significance and accounts for patients seeking medical attention (Woolf, 2010). Classification of pain based on speed include fast/first pain (pin prick pain) which is a sharp, localized and last no longer than the applied stimulus usually accompanied by withdrawal reflex (Motoc et al., 2010). Secondary/second pain (true pain) is characterized as burning, aching, longer lasting and mediated by inflammatory substances as a result of tissue damage (Motoc et al., 2010; Meintjes, 2012). Pain can also be classified as physiologic and clinical pain (neuropathic and inflammatory pain) Clinical pain can arise either from damage to the nervous system (neuropathic pain) or inflammatory states (inflammatory pain) (Cury et al., 2011). Chronic pain can be described as pain said to have persisted for more than 30 days, 3 months, 6 months or 12 months. Chronic pain is sometimes referred to as persistent pain. It could be described as pain that extends beyond the expected period of healing while acute pain is typically temporary; resulting from traumatic tissue injury or infection and it is generally limited in duration (Vadivelu et al., 2009; Meintjes, 2012). Chronic pain may have multiple causes and characterized by gradual onset, may be symptom or diagnosis, serves no adaptive purpose and may be refractory to treatment. Acute pain usually results from obvious tissue damage, has distinct onset, it is well localized, resolves after healing, has a useful biologic purpose and responds effectively to treatment (Vadivelu et al., 2009; Sweiboda et al., 2013). Nociception Perception of pain involves the activation of peripheral nociceptors, generation of a nerve signal and the transmission of this signal to the somatosensory cortex (Merighi et al., 2008). Conveyance of nociceptive stimuli follow different pathways which consist at least three neurons; (i) a first order sensory neuron in the dorsal root ganglia (DRGs); (ii) a second order neuron in the spinal cord dorsal horn; (iii) a third order neuron which is generally located in the ventral posterolateral nucleus of the thalamus (Merighi et al., 2008). Peripheral nervous system The pseudounipolar sensory neurons have a cell body in the dorsal root ganglion (DRG) or the trigeminal ganglion and axonal projections that terminate in the periphery and the dorsal horn of the spinal cord. Thus, nociceptive stimuli applied at the periphery result in release of excitatory neurotransmitters in the CNS. The nociceptors are either small-diameter thinly myelinated A𝛿 fibers or unmyelinated C-fibers. The A𝛿 nociceptors are subdivided into the Type I nociceptors, that respond preferentially to strong mechanical or chemical stimuli, but can also respond to high (>50∘C) temperatures, and the Type II nociceptors, that respond preferentially to noxious thermal stimuli over mechanical stimuli. Whereas most C-fiber nociceptors are polymodal, responding to thermal, mechanical, and chemical stimuli, there are subpopulations of C- fiber that are selectively heat sensitive or mechanosensitive (Ossipov, 2012). Transduction Mechanisms Many stimuli have been found to activate ion channels present on nociceptor terminals that act as molecular transducers to depolarize these neurons, thereby setting off nociceptive impulses along the pain pathways. Among these ion channels are the members of the transient receptor potential (TRP) family. To date, the most studied member of the TRP family is the TRPV1 receptor (Rosenbaum and Simon 2007). Noxious signals are transduced into activation of sensory ion channels. The TRP channels are seemingly the most investigated of these channels that contribute to nociceptive processing. Opening the pore allows influx of Na+ and Ca2+, resulting in depolarization and generation of an action potential. The TRPV1 channel, initially identified as the vanilloid receptor 1 (VR1), was the first “pain” channel to be discovered and was characterized by its activation by noxious heat (temperatures >43∘C), low pH (<6) and by capsaicin, the ingredient in hot peppers responsible for the burning sensation. The TRPV1 channel is found on most heat-sensitive C and A𝛿 nociceptors. Other channels involved in the transduction of pain include; the degenerin/epithelial Na+ channel family (DEG/ENaC), the acid-sensing channels (ASIC). Central Nervous System (CNS) Ascending Pathways The central terminals of the peripheral sensory fibers enter the CNS through the dorsal horn of the spinal cord. The substantia gelatinosa, consisting of laminae I and lamina II outer, receives inputs from myelinated A𝛿 nociceptors and the peptidergic unmyelinated C-fiber nociceptors, and most of the nonpeptidergic C-fiber nociceptors terminate on interneurons of the inner lamina II. The deeper laminae, III through V, receive inputs from the large-diameter myelinated A𝛽 fibers, which normally transmit innocuous sensory inputs. Moreover, the wide dynamic range neurons of lamina V receive inputs from nonnociceptive primary afferents and from A𝛿 nociceptors and also receive indirect inputs from C-fibers terminating on lamina II interneurons via multisynaptic projections. Neurons of laminae I and V project along the spinothalamic and spinoreticulothalamic tracts to supraspinal sites such as the thalamus, parabrachial nucleus, and amygdala, where pain signals are processed and sent on to higher cortical centers. The central terminals of the primary afferent neurons release the excitatory neurotransmitters glutamate, substance P and CGRP to activate the second order neurons of the spinal dorsal horn (Ossipov, 2012). Descending Pathways The periaqueductal grey (PAG) is the source of descending opioid-mediated inhibition of nociceptive inputs. The PAG receives nociceptive inputs from the spinal cord through connections with the parabrachial nucleus. Neuroanatomical studies revealed that the PAG sends projections to noradrenergic pontine nuclei and the rostroventromedial medulla (RVM), resulting in inhibition of nociceptive inputs at the level of the spinal cord by the release of norepinephrine and serotonin. Bidirectional Pathways. Along with the inputs from the PAG, the RVM also communicates with the noradrenergic nucleus locus coeruleus and the thalamus and is considered to be the final common relay in descending modulation of nociceptive inputs. Numerous early studies showed that electrical stimulation or morphine microinjection in the RVM produced antinociception in animal models. The RVM sends projections to the dorsal horn of the spinal cord and to the trigeminal nucleus caudalis and forms synapses with interneurons or second-order neurons that send ascending nociceptive projections. Several electrophysiologic and behavioral studies indicate that the RVM produces “bidirectional” pain modulation, in that it can inhibit or enhance nociceptive inputs. RVM stimulation facilitates, and higher levels of stimulation inhibits, nocifensive responses in the rat. This property of the RVM may play a significant role in endogenous pain inhibitory systems as well as maintenance of enhanced abnormal pain states. Neuropathic pain Neuropathic pain can develop after nerve injury, when deleterious changes occur in injured neurons and along nociceptive and descending modulatory pathways in the central nervous system. The myriad neurotransmitters and other substances involved in the development and maintenance of neuropathic pain also play a part in other neurobiological disorders. The International Association for the Study of Pain (IASP) defined neuropathic pain (NP) as “ pain initiated or caused by a primary lesion or dysfunction of the nervous system. An alternative definition was proposed by the IASP Neuropathic Pain Special Interest Group as pain emerging as a direct consequence of a lesion or a disease of the somatosensory systems. Neuropathic pain is generally characterized by the sensory abnormalities such as unpleasant abnormal sensation (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to a stimulus that does not normally provoke pain (allodynia) (Kaur et al., 2010) Peripheral neuropathic pain is frequently observed in patients with cancer, AIDS, long-standing diabetes, lumbar disc syndrome, herpes infection, traumatic spinal cord injury (SCI), multiple sclerosis and stroke. Mechanisms of Neuropathic pain Neuropathic pain can result from nerve injury or disease affecting the peripheral or central nervous system. Nerve damage may result from compression, ischemia, metabolic, traumatic, toxic, infectious, immune mediated or even hereditary (Rathmell and Fine, 2012). Peripheral Mechanisms Neuropathic pain commonly affects the nociceptive pathways. Pathological changes have been described in peripheral axons and dorsal root ganglia after nerve lesions and have been the underlying the mechanisms of Neuropathic pain. This peripheral neuropathies that usually involve selectively the large (Aα and Aβ) fibers do not normally cause pain while those affecting small nerve fibers (c nerve fibres) are mostly painful (Raja and Sommer, 2014). The following have reported to be involved in the mechanism of peripheral neuropathies: 1. Ectopic discharges in lesioned fibers and their corresponding ganglia. 2. Abnormal activity in axons undamaged by the lesion. 3. Phenotypic switch 4. Alterations in the expression and regulation of intracellular Ca2+ ion and modulatory receptors on primary afferent terminals. 5. Neuroimmune interactions resulting in enhanced and/or altered production of inflammatory signaling molecules. 6. Sensory-sympathetic coupling and other alterations in receptor signaling. 7. Disinhibition. Ectopic Discharges in Injured Fibers This may be described as spontaneous production action potential within the injured axon due to alteration of voltage gated Na channels. These alterations may either lead to excessive activity or loss of function. K+ ion hyperpolarization may also be involved leading membrane instability thus spontaneous activity. Generation of spontaneous action potential may also occur in uninjured adjacent nerve fibres as a result of a process called “ephaptic transmission”. Abnormal activity in axons not damaged by lesions Lesions that involve the distal to the dorsal root ganglia leads to Wallerian degeneration that develops into inflammation, activation of macrophage and edema in the axon separated from the cell body. All these encourage abnormal activities in the neuron which may involve overexpression of TRPV1, neurochemicals, neutrophic factors (BDNF), pronociceptive neurotransmitters (CGRP) and abnormal discharges from neurons. Alterations in the Expression ion channels on Primary Afferent Terminals Over expression of sodium channels in the dorsal root ganglia and around the injury site contributes to spontaneous firing of nerve fibres. After nerve damage the increase in expression of sodium channels may lead to ectopic discharge, lower stimulation threshold and subsequently spontaneous pain. Several drugs such as carbamazepine, act through the blockade of sodium channels. Calcium channels and plays a role in neuropathic pain. Calcium influx is required for release of neurotransmitters from nociceptive terminal. Thus overexpression of Ca2+ channel in the dorsal ganglia can cause excessive release of pronociceptive neurotransmitters like glutamate which is the major excitatory neurotransmitter. This calcium channels are primary targets of Gabapentin in the treatment of neuropathic pain. Neuroimmune Interactions Resulting in Enhanced and/or Altered Production of Inflammatory Signaling Molecules Nerve injury have been reported with increasing frequency to be associated with activation of peripheral immune system which can alter sensory processing. Cytokines and chemokines like interleukins (IL-1β, IL-6), TNFα etc released from immune cells can cause sensitization of channels resulting in firing of nociceptors. These inflammatory cytokines play a crucial role in inflammatory response after nerve injury through intracellular mediators like protein kinase C and cAMP resulting in allodynia and hyperalgesia. Sensory-Sympathetic Coupling (Sympathetic maintained pain) Sympathetically maintained pain is pain that is enhanced or maintained by an abnormality in the sympathetic nervous system. It occurs as a result of functional coupling of sympathetic nerves and somatosensory nerves after nerve injury (Cohen and Mao, 2014). Sympathetically maintained pain is most commonly associated with complex regional pain syndrome as well as postherpetic neuralgia. Nerve growth factor (NGF) is crucial for the development and maintenance of small-diameter somatic and sympathetic neurons most which have nociceptive function (McMahon and Bennet, 1994, Garcia-Larrea, 2014). NGF have been reported to induce neuronal sprouting and behavioural signs of hyperalgesia in rats. Increased levels of NGF induces sympathetic neurons innervating blood vessels in the dorsal root ganglia to send new sprouting branches towards the ganglion neuron themselves. Norepinephrine produced in these fiber elicits abnormal discharges of polymodal nociceptors, which also express abnormally increased levels of α-adrenoceptors in their axon and soma. It has been reported nonlesioned unmyelinated nociceptors projecting into a damaged peripheral nerve start to develop a low activation discharge and can acquire a novel sensitivity to catecholamines Adrenergic receptor–bearing neurons become so sensitive that they may respond to circulating norepinephrine, and this mechanism might contribute to a number of “sympathetically maintained” or complex regional pain syndromes previously called sympathetic dystrophy. These data also support the therapeutic use of sympathetic block to treat complex regional pain syndromes. Central Mechanisms Within the central nervous systems the nociceptive system is also affected but it is mostly associated with loss of thermoalgesic sensitivity. Hyperexcitability of second-order neurons, selective neuronal loss, failure of inhibitory mechanisms, and structural reorganization have each been suggested or experimentally demonstrated after lesions inducing Neuropathic pain. The most crucial in the central mechanism of neuropathic pain is central sensitization, which is defined as an abnormal increase of spontaneous and evoked activity of CNS nociceptive neurons. Central sensitization exists at both the spinal and supraspinal levels, though studies in the spinal dorsal horn have been extensively investigated. Central sensitization is mostly characterized by primary hyperalgesia to mechanothermal stimuli at the level of the lesion, and secondary hyperalgesia to mechanical stimuli over non-affected sites around the lesion. Central sensitization is characterized by increases in the spontaneous activity, evoked responses and of the receptive field, the presence of neuronal after discharge, and lowered response thresholds of wide dynamic range (WDR) dorsal horn neurons. This in turn results in activation of downstream signaling cascades that, by modulating NMDA receptor activity, enhance neuronal excitability. These proexcitatory neuroplastic changes suggest that enhanced pain states are mediated in part by development of long term potentiation. The peripheral changes described above provide a number of plausible mechanisms leading to sensitization including abnormal ectopic discharges in injured fibers, abnormal hyperexcitability of noninjured C fibers. Repeated and exaggerated discharge of spinal nociceptive neurons via the mechanisms described above gives rise to phenomenon termed long-term potentiation (LTP), defined as an increase in synaptic efficacy (i.e., increased probability of fi ring) resulting from coincident activity of pre- and postsynaptic elements. This phenomenon brings about a facilitation of chemical transmission that lasts for hours in vitro and that can persist for periods of weeks or months in vivo. Disinhibition Once a nociceptive stimulus is transmitted to higher cortical centers, a series of events occurs that results in the activation of inhibitory neurons that attenuate pain. At the spinal cord level, there is increased release of GABA and glycine from primary afferent terminals, and enhanced activity in inhibitory GABAergic and glycinergic dorsal horn interneurons. After nerve injury, a loss of inhibitory currents occurs as a result of dysfunctional GABA production and release mechanisms; impaired intracellular homeostasis from reduced activity of K+ Cl− cotransporter or increased activity of Na+ K - Cl− cotransporter (or both), leading to increased Cl− levels; and apoptosis of spinal inhibitory interneurons. Loss of inhibitory control has been shown to provoke tactile allodynia and hyperalgesia, and to facilitate structural changes that increase transmission from Aβ fibers that normally transmit non-painful stimuli to nociceptive specific secondary order neurons in the dorsal horn. Conclusion Injury or damage to peripheral or central nervous systems results in maladaptive changes in neurons involved in nociceptive processing that can cause neuropathic pain. It is a disease rather than a symptom. A plethora of mechanisms have been identified to play crucial role in neuropathic pain and some of them overlap despite the current evidence supports mechanism based treatments these overlaps of mechanism makes it difficult because one treatment may not be effective in managing the pain. Reference Cohen, S.P and Mao, J. (2014). Neuropathic pain: mechanisms and their clinical implications. BMJ 2014;348:f7656 doi: 10.1136/bmj.f7656. Garcia-Larrea, L. (2014). The Pathophysiology of Neuropathic Pain: Critical Review of Models and Mechanisms. Srinivasa N. Raja and Claudia L. Sommer (ds). Pain 2014: Refresher Courses, 15th World Congress on Pain IASP Press, Washington, D.C. c 2014:453-474 Jaggi, A.S., Jain, V. and Singh, N. (2009). Animal models of neuropathic pain. Fundamental and Clinical Pharmacology. doi: 10.1111/j.1472-8206.2009.00801.x. Kaur, G., Jaggi, A.S. and Singh, N. (2010). Exploring the potential effect of Ocimum sanctum in vincristine-induced neuropathic pain in rats. Journal of Brachial Plexus and Peripheral Nerve Injury 2010, 5:3. Koltzenburg, M. and Scadding, J. (2001). Neuropathic pain. Curr Opin Neurol 14:641-647. McMahon, S.B. and Bennett. D.L.H. (1997). Growth factors and pain. In: The pharmacology of pain. Dickenson A, Besson J-M (editors). Berlin: Springer Verlag: 135-165. Meintjes, R.A. (2012). An overview of the physiology of pain for the veterinarian. The Veterinary Journal, 193: 344-348. Merskey, H.and Bogduk, N. (1994).International Associatation for the Study of Pain (IASP). Task force on taxonomy: Classification of chronic pain, IASP Press, Seattle (WA).pp: 1-238. Mert , T., Ocal, I., Cinar, E., Yalcin, M.S. and Gunay, I. (2013). Pain relieving effects of pulsed magnetic fields in a rat model of carrageenan-induced hind-paw inflammation. International Journal of Radiation Biology, DOI: 10.3109/09553002.2013.835501 Motoc, D. Turtoi,N.C., Vasca,V., Vasca, E. and Schneider, F.(2010). Physiology of pain-General mechanisms and individual differences, Jurnal Medical Aradean (Arad Medical Journal), 13(4): 19-23. Onge, E.L. Miller, S.A. (2008). Pain associated with diabetic peripheral neuropathy. Continuing Education credit. 33(3): 166-179. Ossipov, M.H. (2012). The Perception and Endogenous Modulation of Pain. Scientifica Ramin Raouf, Kathryn Quick, and John N. Wood (2010).Pain as a channelopathy. J Clin Invest.,120 (11):3745–3752. Rathmel, J.P. and Fine, P (2012). Pain TV: Rationale for treatment: Focus on Neuropathic Pain (Transcript). Medscape Education Family Medicine. (Accessed on 19/11/2015) Available at http://www.medscape.org/viewarticle/754961_transcript). Rosenbaum, T. and Simon, S.A.(2007). TRPV1 Receptors and Signal Transduction. Liedtke WB, Heller S, editors. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Boca Raton (FL): CRC Press; 2007. Vadivelu, N, Whitney, C.J. and. Sinatra, R.S.(2009). Pain Pathways and Acute Pain Processing. In:Acute pain management. (Sinatra, R.S. de Leon-Casasola, O.A., Ginsberg, B. and Viscusi, E.R. (Editors). Cambridge University Press, United Kingdom. pp: 3-17. Volume 2012, Article ID 561761, 1-25. Woolf, C.J. (2010). What is the thing called pain? Journal of Clinical Investigation, 120(11): 37423744.